Citius Pharmaceuticals, Inc.

8-K · ea0292904-8k_citius.htm iXBRL

0001506251

 2026-06-01
 2026-06-01

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

 FORM 8-K

  

 CURRENT REPORT

 Pursuant to Section 13 or 15(d) of

 the Securities Exchange Act of 1934

  

 Date of Report (Date of earliest event reported)
 June 1, 2026

  

 Citius Pharmaceuticals, Inc.

 (Exact name of registrant as specified in its charter)

  

 Nevada

 (State or other jurisdiction of incorporation)

  

 001-38174
  
 27-3425913

 (Commission File Number)
  
 (IRS Employer

Identification No.)

  

 11 Commerce Drive , 1st Floor ,

 Cranford , NJ

  
 07016

 (Address of principal executive offices)
  
 (Zip Code)

  

 Registrant’s telephone number, including area code
 ( 908 ) 967-6677

  

 Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:

  

 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  

 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b) of the Act:

  

 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 Common stock, $0.001 par value
  
 CTXR
  
 The Nasdaq Capital Market

  

 Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☐

  

 If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item 8.01 Other Events.

  

 On June 1, 2026, our wholly-owned
subsidiary, Citius Oncology, Inc., issued a press release announcing the presentation of clinical data at the Annual Meeting of the American
Society of Clinical Oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

  

 Item 9.01. Financial Statements and Exhibits.

  

 (d) Exhibits

  

 Exhibit No.
  
 Description

 99.1
  
 Press release, dated June 1, 2026.

 104
  
 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

  

 1

  

  

 SIGNATURES

  

 Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

  

 Date: June 1, 2026
 CITIUS PHARMACEUTICALS, INC.

  
  
  

  
 By:
 /s/ Leonard Mazur                           

  
  
 Leonard Mazur

  
  
 Chairman and Chief Executive Officer

  

 2